The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | FOLFIRI-ramucirumab vs ramucirumab-paclitaxel in the 2L for upper gastrointestinal cancer
Timothy Brown, MD, UT Southwestern Medical Center, Dallas, TX, comments on the efficacy of FOLFIRI with ramucirumab compared to ramucirumab and paclitaxel in the treatment of upper GI cancers. Dr Brown highlights that a nationwide cohort analysis using the Flatiron Health database found no statistical difference in overall survival between the two regimens, suggesting that FOLFIRI with ramucirumab may be an equivocal alternative to ramucirumab and paclitaxel. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
